Hayyoung Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hayyoung Lee has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Young Sang Kim
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea
32 shared publications - Jie-Oh Lee
Department of Life Sciences, POSTECH Biotech Center, Pohang University of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang-si 37673, Republic of Korea
31 shared publications - Van Anh Do-Thi
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea
26 shared publications - Sang Min Park
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea
25 shared publications - Geunyoung Cho
Institute of Membrane Proteins, POSTECH, Pohang, Republic of South Korea
23 shared publications - Hye Jin Jeong
Institute of Membrane Proteins, POSTECH, Pohang, Republic of South Korea
23 shared publications
Latest Publications
- Open Access
Integrating Fas-mediated apoptosis with IFNγ signaling to drive tumor regression in mRNA cancer therapeutics
For mRNA-based cancer gene therapy, we engineered a membrane-bound fusion protein combining interferon-γ (IFNγ) with the Fas intracellular domain (FasICD) to couple local IFNγ signaling with Fas-driven apoptotic tumor cell death. IFNγ–FasICD was robustly expressed on the plasma membrane after mRNA transfection. In murine cancer cell lines, IFNγ–FasICD mRNA reduced viability within 24 h, resulting in ∼50% cell death in MC38 cells and ∼75% in B16OVA cells, exceeding the cytotoxicity of the FasICD-deleted control (IFNγ–FasΔ). Mechanistically, IFNγ–FasICD induced predominantly apoptotic rather than necrotic cell death. IFNγ–FasICD also activated IFNγ receptor signaling in both cancer and the immune cells, inducing IFNγ-responsive genes in IFNγR-high B16OVA cells and triggering STAT1 phosphorylation in co-cultured splenocytes. For in vivo delivery, IFNγ–FasICD mRNA was formulated in lipid nanoparticles (LNPs), enabling strong intratumoral expression that peaked at ∼3 h and persisted for more than 48 h. Repeated intratumoral injections of LNP-formulated IFNγ–FasICD mRNA suppressed the growth of established B16OVA and MC38 tumors and improved survival, with ∼40% and ∼20% of mice surviving beyond 30 days, respectively. IFNγ–FasICD treatment remodeled the tumor microenvironment by increasing tumor-infiltrating CD45 + cells and CD8 + T cells, while further reducing FOXP3 + regulatory T cells. Moreover, NK/NKT cells and cDC1/cDC2 populations were increased, and their activation was enhanced. In tumor-draining lymph nodes, IFNγ–FasICD mRNA promoted dendritic cell migration and increased priming and differentiation of CD8 + T cells toward effector and memory phenotypes, accompanied by enhanced functional activation of IFNγ-producing CD8 + T cells and highly cytotoxic NK cells in peripheral blood. Overall, our findings provide a mechanistic foundation for cytokine–death receptor fusion proteins as an in vivo antitumor strategy that can reprogram tumor cells into localized sources of both apoptotic signals and immune-activating cues.
Open AccessIntegrating Fas-mediated apoptosis with IFNγ signaling to drive tumor regression in mRNA cancer therapeutics
For mRNA-based cancer gene therapy, we engineered a membrane-bound fusion protein combining interferon-γ (IFNγ) with the Fas intracellular domain (FasICD) to couple local IFNγ signaling with Fas-driven apoptotic tumor cell death. IFNγ–FasICD was robustly expressed on the plasma membrane after mRNA transfection. In murine cancer cell lines, IFNγ–FasICD mRNA reduced viability within 24 h, resulting in ∼50% cell death in MC38 cells and ∼75% in B16OVA cells, exceeding the cytotoxicity of the FasICD-deleted control (IFNγ–FasΔ). Mechanistically, IFNγ–FasICD induced predominantly apoptotic rather than necrotic cell death. IFNγ–FasICD also activated IFNγ receptor signaling in both cancer and the immune cells, inducing IFNγ-responsive genes in IFNγR-high B16OVA cells and triggering STAT1 phosphorylation in co-cultured splenocytes. For in vivo delivery, IFNγ–FasICD mRNA was formulated in lipid nanoparticles (LNPs), enabling strong intratumoral expression that peaked at ∼3 h and persisted for more than 48 h. Repeated intratumoral injections of LNP-formulated IFNγ–FasICD mRNA suppressed the growth of established B16OVA and MC38 tumors and improved survival, with ∼40% and ∼20% of mice surviving beyond 30 days, respectively. IFNγ–FasICD treatment remodeled the tumor microenvironment by increasing tumor-infiltrating CD45 + cells and CD8 + T cells, while further reducing FOXP3 + regulatory T cells. Moreover, NK/NKT cells and cDC1/cDC2 populations were increased, and their activation was enhanced. In tumor-draining lymph nodes, IFNγ–FasICD mRNA promoted dendritic cell migration and increased priming and differentiation of CD8 + T cells toward effector and memory phenotypes, accompanied by enhanced functional activation of IFNγ-producing CD8 + T cells and highly cytotoxic NK cells in peripheral blood. Overall, our findings provide a mechanistic foundation for cytokine–death receptor fusion proteins as an in vivo antitumor strategy that can reprogram tumor cells into localized sources of both apoptotic signals and immune-activating cues.
- Open Access
- 2 January 2025
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 29 (1) , 46-56
The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells
Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas. The tumor cells expressing sIFNγ and mbIFNγ/Fas showed slower growth rates compared to the mock-transfected cells. Furthermore, the tumorigenicity of the CT26 cells expressing mbIFNγ/Fas was significantly lower than that of cells expressing sIFNγ or the mock control. Remarkably, about 85% of the mice injected with the mbIFNγ/Fas-expressing tumors remained tumor-free for over two months. Mice that rejected mbIFNγ/Fas-expressing tumors developed systemic anti-tumor immunity against CT26 cells, which was characterized by enhanced levels of CD4+ and CD8+ T cells, as well as natural killer (NK) cells. Interestingly, splenocytes activated with the mbIFNγ/Fas-expressing tumors exhibited higher cytotoxicity than those activated with tumor cells expressing sIFNγ. These findings suggest that expressing the mbIFNγ/Fas chimera in tumor cells could be a promising strategy for developing whole tumor cell vaccines or gene therapies for cancer immunotherapy.
- 2 January 2025
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 29 (1) , 46-56
Open AccessThe anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells
Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas. The tumor cells expressing sIFNγ and mbIFNγ/Fas showed slower growth rates compared to the mock-transfected cells. Furthermore, the tumorigenicity of the CT26 cells expressing mbIFNγ/Fas was significantly lower than that of cells expressing sIFNγ or the mock control. Remarkably, about 85% of the mice injected with the mbIFNγ/Fas-expressing tumors remained tumor-free for over two months. Mice that rejected mbIFNγ/Fas-expressing tumors developed systemic anti-tumor immunity against CT26 cells, which was characterized by enhanced levels of CD4+ and CD8+ T cells, as well as natural killer (NK) cells. Interestingly, splenocytes activated with the mbIFNγ/Fas-expressing tumors exhibited higher cytotoxicity than those activated with tumor cells expressing sIFNγ. These findings suggest that expressing the mbIFNγ/Fas chimera in tumor cells could be a promising strategy for developing whole tumor cell vaccines or gene therapies for cancer immunotherapy.
- Open Access
6′-Sialyllactose Alleviates Muscle Fatigue through Reduced Blood Lactate Level after Treadmill Exercise in Mice
6′-Sialyllactose (6′-SL), found in human breast milk, exhibits anti-inflammatory, immune function-enhancing, brain development-promoting, and gut health-improving effects. However, its effects on muscle fatigue remain unknown. Here, we aimed to investigate the effects of 6′-SL on blood lactate level, muscle fiber type, and oxidative phosphorylation protein complexes (OXPHOS) in muscle after exercise using C57BL/6J male mice. C57BL/6J mice were randomly assigned to control or 100 mg/kg 6′-SL. After 12 weeks of 6′-SL administration, the mice were made to perform treadmill exercise; their blood lactate and glucose levels were measured at the basal level (rest) and 0, 5, and 10 min after treadmill exercise. Results showed that 6′-SL treatment in C57BL/6J mice significantly reduced blood lactate level and improved blood glucose level. Moreover, 6′-SL increased the expression of slow-myosin heavy chain (MHC) and OXPHOS in gastrocnemius muscle. In addition, 6′-SL treatment for 12 weeks did not affect food intake, serum biomarkers of tissue injury, and lipid profiles compared with those of the controls. These findings indicate that non-toxic 6′-SL suppressed muscle fatigue during exercise by promoting protein expression of muscle fibers, especially slow-twitch muscle fibers characterized by abundant OXPHOS complexes and decreased blood lactate level. This study suggests that 6′-SL holds promise as a nutritional supplement in exercise and clinical settings, subject to further validation.
Open Access6′-Sialyllactose Alleviates Muscle Fatigue through Reduced Blood Lactate Level after Treadmill Exercise in Mice
6′-Sialyllactose (6′-SL), found in human breast milk, exhibits anti-inflammatory, immune function-enhancing, brain development-promoting, and gut health-improving effects. However, its effects on muscle fatigue remain unknown. Here, we aimed to investigate the effects of 6′-SL on blood lactate level, muscle fiber type, and oxidative phosphorylation protein complexes (OXPHOS) in muscle after exercise using C57BL/6J male mice. C57BL/6J mice were randomly assigned to control or 100 mg/kg 6′-SL. After 12 weeks of 6′-SL administration, the mice were made to perform treadmill exercise; their blood lactate and glucose levels were measured at the basal level (rest) and 0, 5, and 10 min after treadmill exercise. Results showed that 6′-SL treatment in C57BL/6J mice significantly reduced blood lactate level and improved blood glucose level. Moreover, 6′-SL increased the expression of slow-myosin heavy chain (MHC) and OXPHOS in gastrocnemius muscle. In addition, 6′-SL treatment for 12 weeks did not affect food intake, serum biomarkers of tissue injury, and lipid profiles compared with those of the controls. These findings indicate that non-toxic 6′-SL suppressed muscle fatigue during exercise by promoting protein expression of muscle fibers, especially slow-twitch muscle fibers characterized by abundant OXPHOS complexes and decreased blood lactate level. This study suggests that 6′-SL holds promise as a nutritional supplement in exercise and clinical settings, subject to further validation.
- Open Access
6′-Sialyllactose Enhances Exercise Performance via Increased Muscle Mass and Strength
Sialyllactose (SL) is a functional human milk oligosaccharide essential for immune support, brain development, intestinal maturation, and antiviral defense. However, despite its established health benefits, the effect of SL on exercise performance and muscle mass in mice remains unknown. Here, we aimed to investigate, for the first time, the effects of 6′-SL on muscle functions. Seven-week-old male C57BL/6J mice were administered 100 mg/kg 6′-SL for 12 weeks, after which exhaustive treadmill performance was conducted. Moreover, muscle strength was examined by grip strength, and muscle phenotype characteristics such as muscle mass, muscle fiber size, and muscle protein expression were also examined. The administration of 6′-SL significantly improved exhaustive treadmill performance metrics, including distance and exhaustion time. Grip strength was also increased by 6′-SL administration. Additionally, 6′-SL increased muscle mass in both the gastrocnemius (GAS) and soleus. 6′-SL administration led to an increase in the minimum Feret’s diameter and the protein expression of total myosin heavy chain in the GAS muscle. In conclusion, 6′-SL administration in vivo led to increased running distance and time by increasing muscle mass and strength. These findings collectively indicate that 6′-SL is a potential agent for improving muscle health and exercise performance.
Open Access6′-Sialyllactose Enhances Exercise Performance via Increased Muscle Mass and Strength
Sialyllactose (SL) is a functional human milk oligosaccharide essential for immune support, brain development, intestinal maturation, and antiviral defense. However, despite its established health benefits, the effect of SL on exercise performance and muscle mass in mice remains unknown. Here, we aimed to investigate, for the first time, the effects of 6′-SL on muscle functions. Seven-week-old male C57BL/6J mice were administered 100 mg/kg 6′-SL for 12 weeks, after which exhaustive treadmill performance was conducted. Moreover, muscle strength was examined by grip strength, and muscle phenotype characteristics such as muscle mass, muscle fiber size, and muscle protein expression were also examined. The administration of 6′-SL significantly improved exhaustive treadmill performance metrics, including distance and exhaustion time. Grip strength was also increased by 6′-SL administration. Additionally, 6′-SL increased muscle mass in both the gastrocnemius (GAS) and soleus. 6′-SL administration led to an increase in the minimum Feret’s diameter and the protein expression of total myosin heavy chain in the GAS muscle. In conclusion, 6′-SL administration in vivo led to increased running distance and time by increasing muscle mass and strength. These findings collectively indicate that 6′-SL is a potential agent for improving muscle health and exercise performance.
- Open Access
- 24 July 2024
- Published by MDPI AG in Preprints.org
6′-Sialyllactose Enhances Exercise Performance via Increased Muscle Mass and Strength
Sialyllactose (SL) is a functional human milk oligosaccharide essential for immune support, brain development, intestinal maturation, and antiviral defense. However, despite its established health benefits, the effect of SL on exercise performance and muscle mass in mice remains unknown. Here, we aimed to investigate, for the first time, the effects of 6′-SL on muscle functions. Seven-week-old male C57BL/6J mice were administered 100 mg/kg 6′-SL for 12 weeks, after which exhaustive treadmill performance, muscle strength, and muscle phenotype were examined. The administration of 6′-SL significantly improved exhaustive treadmill performance metrics, including distance and exhaustion time. Grip strength was also increased by 6′-SL administration. Additionally, 6′-SL increased muscle mass in both the gastrocnemius (GAS) and soleus. 6′-SL administration led to an increase in the minimum Feret’s diameter and the protein expression of total myosin heavy chain in the GAS muscle. In conclusion, 6′-SL administration in vivo led to increased running distance and time by increasing muscle mass and strength. These findings collectively indicate that 6′-SL is a potential agent for improving muscle health and exercise performance.
- 24 July 2024
- Published by MDPI AG in Preprints.org
Open Access6′-Sialyllactose Enhances Exercise Performance via Increased Muscle Mass and Strength
Sialyllactose (SL) is a functional human milk oligosaccharide essential for immune support, brain development, intestinal maturation, and antiviral defense. However, despite its established health benefits, the effect of SL on exercise performance and muscle mass in mice remains unknown. Here, we aimed to investigate, for the first time, the effects of 6′-SL on muscle functions. Seven-week-old male C57BL/6J mice were administered 100 mg/kg 6′-SL for 12 weeks, after which exhaustive treadmill performance, muscle strength, and muscle phenotype were examined. The administration of 6′-SL significantly improved exhaustive treadmill performance metrics, including distance and exhaustion time. Grip strength was also increased by 6′-SL administration. Additionally, 6′-SL increased muscle mass in both the gastrocnemius (GAS) and soleus. 6′-SL administration led to an increase in the minimum Feret’s diameter and the protein expression of total myosin heavy chain in the GAS muscle. In conclusion, 6′-SL administration in vivo led to increased running distance and time by increasing muscle mass and strength. These findings collectively indicate that 6′-SL is a potential agent for improving muscle health and exercise performance.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Gating strategy to analyze the chemotactic migration of immune cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Gating strategy to analyze the chemotactic migration of immune cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
IL-9 promotes M1 polarization of macrophages in vitro
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
IL-9 promotes M1 polarization of macrophages in vitro
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Bodyweight change of the tumor-implanted mice in Figure 6
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Bodyweight change of the tumor-implanted mice in Figure 6